Home

David P Bonita

CIK 1572451 · last filed 2026-06-18

David P Bonita is a corporate insider who has filed 75 SEC Form 4 insider transactions across 12 companies since 2013. The most recent filing, for IMA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$26.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $23.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$23.43M

Companies

12

Total Filings

75

Lifetime Open-Market Net

$26.49M

Filer Profile

Reported Address
C/O ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK, NY 10022
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IMA Director 753,441 $5.08 $3.83M $2.50M 3 2026-06-18
PRLD Director 1,126,126 $4.59 $5.17M $41.00M 10 2026-06-10
Repare Therapeutics Inc. (RPTX) Delisted Director 3,177,041 $2.65 $8.42M $11.29M 11 2024-06-20
Third Harmonic Bio, Inc. (THRD) Delisted Director 5,779,071 $5.38 $31.09M $5.10M 5 2024-06-10
ImageneBio, Inc. (IKNA) Delisted Director 13,107 $17.16 $224.9K $12.42M 9 2024-06-10
Acutus Medical, Inc. (AFIB) Delisted Director 1,698,183 $0.09 $152.8K $22.47M 6 2023-06-15
Tricida, Inc. (TCDA) Delisted Director 9,274,110 $0.11 $1.00M -$47.11M 9 2022-11-25
Enliven Therapeutics, Inc. (IMRA) Delisted Director 1,049,767 $14.59 $15.32M $35.00M 5 2022-06-03
SIBN Director 785,368 $18.38 $14.44M $3.00M 1 2018-10-19
ViewRay, Inc. (VRAY) Delisted Director 115,613 $0.03 $2.9K $4.35M 4 2018-04-25
Loxo Oncology, Inc. (LOXO) Delisted Director 941,000 — — -$69.20M 9 2017-12-12
AMBIT BIOSCIENCES CORP (AMBI) Delisted Director 13,947 $0.54 $7.5K $5.66M 2 2013-05-24

Recent Filings

75 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 IMA Grant (A) — $0 EDGAR
2026-06-10 PRLD Grant (A) — $0 EDGAR
2026-04-23 PRLD Buy (P) +2,815,315 $12.50M EDGAR
2026-04-16 IMA Buy (P) — $0 EDGAR
2025-08-14 — Other (J) −5,779,071 $0
2025-07-30 IMA Mixed +83,990 $2.50M EDGAR
2025-06-13 PRLD Grant (A) — $0 EDGAR
2024-06-20 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
2024-06-18 PRLD Grant (A) — $0 EDGAR
2024-06-10 Third Harmonic Bio, Inc. (THRD) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 75
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.